Pfizer Inc. (PFE)
| Market Cap | 142.37B |
| Revenue (ttm) | 62.79B |
| Net Income (ttm) | 9.83B |
| Shares Out | 5.69B |
| EPS (ttm) | 1.73 |
| PE Ratio | 14.55 |
| Forward PE | 8.59 |
| Dividend | $1.72 (6.87%) |
| Ex-Dividend Date | Jan 23, 2026 |
| Volume | 47,112,632 |
| Open | 25.01 |
| Previous Close | 25.04 |
| Day's Range | 24.98 - 25.23 |
| 52-Week Range | 20.92 - 27.69 |
| Beta | 0.42 |
| Analysts | Hold |
| Price Target | 27.40 (+9.43%) |
| Earnings Date | Feb 3, 2026 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for PFE stock is "Hold." The 12-month stock price target is $27.4, which is an increase of 9.43% from the latest price.
News
Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, ...
Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun
Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing deal
AbbVie, several other pharma companies near MFN deal with Trump, sources say
AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Tru...
Pfizer Stock Can Sink More. Here Is How
Pfizer (PFE) is encountering threats. Even the most prominent names aren't immune.
Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back
Pfizer Inc (NYSE: PFE) and Merck & Co Inc (NYSE: MRK) aren't exciting stocks anymore — and after a bruising reset, that's starting to look intentional. Pfizer's stock has been back in focus this month...
PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
PADCEV plus Keytruda is the first and only regimen without platinum-based chemotherapy to improve event-free and overall survival when used before and after surgery in cisplatin-eligible patients with...
Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript
Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript
Pfizer falls on disappointing guidance
CNBC's Annika Kim Constantino reports on Pfizer's 2026 guidance.
Pfizer's modest 2026 outlook shows its big investments will take time to pay off
Pfizer forecast modest 2026 guidance as it looks to counter waning Covid product sales and declines from older drugs with longer-term investments in its pipeline. The company expects adjusted profit o...
Here's why Pfizer is revising its revenue forecasts
The drugmaker revised its revenue guidance for 2025, saying it now expects $62 billion in revenue for the year.
Pfizer Stock Edges Higher on 2026 Guidance. Expect a Rough Year for Covid Vaccine Sales.
Pfizer expects revenue and earnings to fall in 2026.
Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings
Pfizer projected 2026 revenue of $59.5 billion to $62.5 billion and adjusted earnings of $2.80 to $3 a share. Wall Street is forecasting 2026 revenue of $61.6 billion and adjusted earnings of $3.05 a ...
Pfizer forecasts 2026 profit below expectations on lower COVID product sales
Pfizer on Tuesday forecast 2026 profit below Wall Street estimates as it expects lower sales of its COVID products, sending its shares down 1.6% in premarket trading.
Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today provided its full-year 2026 guidance(2) while revising its November 4, 2025 full-year 2025 Revenue guidance(2) and reaffirming all other compone...
Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million
Adaptive Biotechnologies said on Monday it has signed two non-exclusive deals with Pfizer to support research in rheumatoid arthritis and other immune-related diseases.
Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis A data licensing agreement to access Adaptive's proprietary TCR-antigen datasets for research ...
Pfizer Declares First-Quarter 2026 Dividend
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company's common stock, payable March 6, 2026, to hol...
Dividend Harvesting Portfolio Week 249: $24,900 Allocated, $2,646.53 In Projected Dividends
The Dividend Harvesting Portfolio remains up 32.60% on invested capital, yielding 8.02%, despite a temporary dip in dividend income from the MSTY reverse split. A dovish Fed rate cut and bullish GDP p...
Health Rounds: Pfizer drug delays progression of advanced breast cancer in trial
Pfizer's Tukysa added to maintenance therapy significantly delayed disease progression in patients with HER2-positive metastatic breast cancer who had responded well to initial treatment, according to...
Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports
Pfizer will cut hundreds of jobs in Switzerland as part of its multi-year cost reduction program, Bloomberg News reported on Wednesday, citing people familiar with the matter.
TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 HER2CLIMB-05 trial of the tyrosine kinase inhibitor TUKYSA® (tucatinib) as part of an investigation...
Will Pfizer's YaoPharma deal deliver a powerful new oral obesity pill?
Pfizer is rolling the dice again on an oral obesity pill. The pharmaceutical giant signed an exclusive global license agreement with YaoPharma, a subsidiary of China's Fosun Pharma.
Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill
Pfizer said it has struck an up to $2.1 billion licensing deal with YaoPharma to develop and commercialize its obesity pill, furthering the pharma company's push into the weight loss space. YaoPharma...
Undisclosed Deaths in the Pfizer mRNA COVID-19 Vaccine Trial Discussed in the Journal of American Physicians and Surgeons
In the rushed emergency use approval of Covid vaccines, deaths were undisclosed. Thousands received shots before warnings of heart damage were released.
Pfizer: The Most Powerful Drug Pipeline In Pharma Could Deliver Major Long-Term Gains
Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, despite near-term headwinds. PFE maintains strong free cash flow and improved gui...